drug CDMO
Scope
Date
~
-
Bio & Pharma
S.Korea's Boryung receives EU GMP certification
South Korean pharmaceutical company Boryung announced that its production facility for anti-cancer injections in Yesan, South Chungcheong Province, ...
Feb 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Chong Kun Dang, Synaffix ink deal to introduce ADC technology
Chong Kun Dang Pharmaceutical Corp. said on Monday that it has signed a contract with Dutch biotechnology firm Synaffix B.V for the use of antibody-...
Feb 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong receives approval for its GERD drug Fexuclue in Ecuador
Daewoong Pharmaceutical said Friday that it has obtained marketing authorization from Ecuador's National Agency for Health Regulation, Control and S...
Feb 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Biopharma submits clinical trial plan in Australia
Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, has applied to the Australian clini...
Feb 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US
South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...
Feb 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Korea's InCerebro to leverage AI to identify drug candidates
South Korean AI-based drug developer InCerebro aims to identify potential drug candidates using molecular modeling technology, according to its CEO ...
Feb 01, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Daewoong Pharmaceutical to export tech to British company
South Korea's Daewoong Pharmaceutical has licensed a new drug candidate for idiopathic pulmonary fibrosis (IPF) to CS Pharmaceuticals (CSP) of the U...
Feb 01, 2023 (Gmt+09:00)
-
Bio & Pharma
JW Pharma to put AI into new drug ingredient development
South Korea's drug developer JW Pharmaceutical is expanding the scope of its artificial intelligence (AI) uses from new drug research to the develop...
Jan 30, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea, Japan compete in gastroesophageal reflux drug market
South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical pr...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Bridge Biotherapeutics, Pinotbio develop lung cancer treatment
South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Inventage Lab launches clinical trials for addiction treatment in Australia
South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics C...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N's K-CAB to get insurance benefits in China
South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
ST Pharm exports $14.6 mn worth of drug ingredients to Europe
ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma's Sanfilippo treatment eligible for FDA priority review
GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture special...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong accelerates investment in CDMO business
Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
JVM to sell fully automated drug inspection machines in US
Hanmi Pharmaceutical Co. said on Monday that it had signed an agreement with Euclid Medical Products, a company specializing in manufacturing drug d...
Jan 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong, Onchorus to undertake research on mRNA anticancer drugs
Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, Neurolive to jointly develop new antidepressant drug
South Korea's drug company Daewoong Pharmaceutical said on Wednesday that it has signed an agreement with biopharmaceutical venture Neurorive to joi...
Dec 28, 2022 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ applies to FDA for trials of immuno-anticancer drug candidate
CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 ...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Dong-A ST incorporates NeuroBo as subsidiary
Dong-A ST said on Friday that it would acquire American drug company NeuroBo Pharmaceuticals as a subsidiary.NeuroBo, located in Boston, is a Nasdaq...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biopharmaceutical sector to see brisk M&As in H1, 2023
An expert says the first half of next year will see the start of brisk M&As in biopharmaceuticals targeting strategic investors.Pyeon Jae-seong,...
Dec 21, 2022 (Gmt+09:00)
-
Artificial intelligence
Syntekabio launches new drug development platform STB Cloud in US
Syntekabio,Inc., a South Korean artificial intelligence (AI) drug development company, said on Monday it has launched its cloud-based AI drug develo...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem in $95.5 million drug out-licensing deal with China’s Innovent
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., and China’s biotech company Innovent Biologics have entered into a strategi...
Dec 15, 2022 (Gmt+09:00)
-
Bio & Pharma
Daewoong submits new drug applications for Fexuclue in 10 countries
South Korea's leading drug company Daewoong Pharmaceutical is accelerating its global expansion efforts for its 34th domestically developed drug Fex...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swis...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem confirms diabetes drug Zemidapa's efficacy in phase 3 trials
LG Chem Ltd. announced in a disclosure on Monday that it had confirmed superior efficacy in phase 3 clinical trials for the combined administration ...
Dec 13, 2022 (Gmt+09:00)
Latest News
- 1 Maybe Happy Ending: How a Seoul-made robot love story rewrote Broadway playbook
- 2 NPS yet to schedule external manager selection; PE firms’ fundraising woes deepen
- 3 Woori Financial wins approval for Tongyang, ABL Life acquisition
- 4 BMW surpasses Mercedes in Korean sales amid imported vehicle market shake-up
- 5 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs